Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
Status:
Active, not recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well sapanisertib works in treating patients with acute
lymphoblastic leukemia that has returned after a period of improvement (relapsed) or has not
responded to previous treatment (refractory). Sapanisertib may stop the growth of cancer
cells by blocking some of the enzymes needed for cell growth.